Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Unknown 10Completed 4Terminated 2Not yet recruiting 2Withdrawn 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2

Conditions

Pancreatic Neoplasms 21Urinary Bladder Neoplasms 8Biliary Tract Neoplasms 7Non-Muscle Invasive Bladder Neoplasms 6Nasopharyngeal Carcinoma 6Nasopharyngeal Neoplasms 5Cholangiocarcinoma 5Ovarian Neoplasms 3Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Breast Neoplasms 3Triple Negative Breast Neoplasms 2Recurrence 2Pancreatic Cancer Resectable 2Neoplasm Metastasis 2Lymphoma, Extranodal NK-T-Cell 2Thyroid Neoplasms 1Rhabdoid Tumor 1Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma 1Rare Tumour 1Pancreatic cancer, adult 1Pancreatic Cancer Non-resectable 1PDAC - Pancreatic Ductal Adenocarcinoma 1Mibc 1Melanoma 1Lung Neoplasms 1Lung Diseases, Interstitial 1Locally Advanced Pancreatic Cancer 1Liver Neoplasms 1Klatskin Tumor 1

Interventions

selinexor 3pegaspargase 3Oxaliplatin 2Gemcitabine 2tislelizumab 1sugemalimab 1Thiotepa 1Radiotherapy 1Immune Checkpoint Inhibitors 1Azacitidine 1Asparaginase 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Not yet recruiting × Lymphoma, Extranodal NK-T-Cell × Gemcitabine × Clear all
NCT05700448 2026-05-27

Study of Sugemalimab (or Placebo) Plus PGemOx Regimen in Participants With Extranodal NK/T-Cell Lymphoma

CStone Pharmaceuticals

Phase 3 Not yet recruiting
150 enrolled
Lymphoid

Lymphoma, Extranodal NK-T-Cell

NCT07554482 2026-04-28

Selinexor Combined With Reduced-Dose Radiotherapy For Early-Stage Extranodal NK/T-Cell Lymphoma

Beijing Tongren Hospital

Phase 2 Not yet recruiting
34 enrolled
Lymphoid

Lymphoma, Extranodal NK-T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡